Twist Bioscience and LakePharma Form Strategic Collaboration to Provide Antibody Discovery and Development ServicesAdded On: 2019-04-04
LakePharma Launches GMP Manufacturing of Recombinant Proteins and Antibodies in the Bay AreaAdded On: 2019-04-02
LakePharma Announces Dedicated Vector Center to Support Gene and Cell TherapyAdded On: 2019-02-26
March 27, 2019
11AM PST | 2PM EST 45 Minutes
Speakers: Brian Zabel, PhD and Raphael Levy, PhD
Hybridoma and display technologies are two gold-standard approaches to identify novel monoclonal antibodies. The LakePharma Antibody Center provides integrated antibody discovery and engineering services to create therapeutic and diagnostic antibodies for drug developers. To showcase some of the capabilities, the team sought to identify two unique sets of antibody antagonists against promising immuno-oncology targets BTLA and TIGIT utilizing the hybridoma platform and phage display libraries, respectively. In this discovery process, highly potent, selective, and functional immune checkpoint inhibitor antibodies, which in some cases perform superior to benchmark comparators, are identified.
In this webinar, we will discuss: